High Throughput Screening (HTS) is a drug-discovery process widely used in the pharmaceutical industry. It leverages automation to quickly assay the biological or biochemical activity of a large number of drug-like compounds. It is a useful for discovering ligands for receptors, enzymes, ion-channels or other pharmacological targets, or pharmacologically profiling a cellular or biochemical pathway of interest. Typically, HTS assays are performed in "automation-friendly" microtiter plates of 96, 384 or 1536 well format.

To this end, the Lead Identification Department at Scripps Florida has set-up a state-of-the art HTS operation that supports Scripps' MLPCN HTS efforts. This department has both HTS and compound management automation, and expertise in adapting biological and biochemical bench-top assays into high-throughput screens.

Lead ID department provides the following capabilities to Scripps Molecular Screening Center:

• Assistance for biomedical researchers with their development of HTS compatible assays.
• Implementation and uHTS of MLPCN assays in 384 and 1536 well format.
• Management of the MLPCN's large (> 100,000 member) compound collection.
• Exploration and implementation of novel technologies for the advancement of HTS.

Inquiries on collborations and capabilities can be made to: - Associate Professor, Head of Lead ID.